Urticaria is an inflammatory skin disorder that affects up to 20% of the world population at
some point during their life. It presents with wheals, angioedema or both due to activation …

These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP),
representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the …

Chronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by
intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously, on a near …

Chronic spontaneous urticaria is characterized by a perivascular non-necrotizing cellular
infiltrate around small venules of the skin. It consists primarily of CD4 (+) lymphocytes, a …

The current therapeutic algorithm for chronic spontaneous urticaria (CSU), endorsed by the
international guideline, entails treatment escalation from second‐generation H1 …

The monoclonal anti‐immunoglobulin E (IgE) antibody, omalizumab, was the first drug
approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who …

Urticaria is a common clinical condition presenting with wheals (hives), angioedema, or
both. Urticaria has a complex pathogenesis, along with a high disease burden, a significant …

Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or
both. In the last years, urticaria has increasingly attracted notice to clinicians and …

Chronic urticaria is defined as the presence of urticaria (hives) for at least 6 weeks with the
assumption that it occurs daily or close to it. If we eliminate physical urticarias and urticarial …

Background Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of
wheals and/or angioedema for≥ 6 weeks. Omalizumab is a monoclonal anti‐IgE antibody …